The European Medicines Agency facilitates access to medicines in low- and middle-income countries.

Discussion: These scientific opinions reflect the conditions of use and rely on high standards, but the final approval decision remains with these countries. Despite the small number of EU-M4all opinions, the many approvals have had an impact and contribute to access to innovation for patients with unmet needs in target countries. PMID: 32053756 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32053756?dopt=Abstract

Source: Pharmacological Reviews - February 12, 2020 Category: Drugs & Pharmacology Authors: Cavaller Bellaubi M, Harvey Allchurch M, Lagalice C, Saint-Raymond A Tags: Expert Rev Clin Pharmacol Source Type: research